Newsroom

Sera Prognostics today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommended stopping enrollment due to efficacy

Sera Prognostics announced that the company will present at the upcoming 35th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City

Salt Lake City – November 8, 2023 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…

Sera Prognostics announced that it will report third quarter fiscal year 2023 financial results on Wednesday, November 8, 2023, after the close of the market.

Sera Prognostics Inc., announced that the company will present at the upcoming Cantor Fitzgerald Global Healthcare Conference 2023 to be held September 26-28, 2023 in New York City.

Salt Lake City – August 9, 2023 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…

Sera Prognostics announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023, after the close of the market.

Sera Prognostics Inc., The Pregnancy Company® announced certain commercial changes and plans to optimize its strategy and commercial structure to highly focus business activities on accelerating test adoption and revenue at significantly reduced operating costs.

Salt Lake City – May 10, 2023 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…

Sera Prognostics Inc., today announced the retirement of the Company’s President and CEO, Gregory C. Critchfield, M.D., M.S., effective June 8, 2023. Zhenya Lindgardt, a member of the Company’s Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President.